Published in Am J Surg Pathol on November 01, 2009
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08
Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells. Aging Cell (2011) 0.99
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr) (2013) 0.96
Pleomorphic lobular carcinoma in a male breast: a rare occurrence. Patholog Res Int (2010) 0.94
Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology (2014) 0.86
Molecular drivers of lobular carcinoma in situ. Breast Cancer Res (2015) 0.86
Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol (2015) 0.83
Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol (2014) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Underestimation rate of lobular intraepithelial neoplasia in vacuum-assisted breast biopsy. Eur Radiol (2014) 0.77
[Lobular neoplasms and invasive lobular breast cancer]. Pathologe (2014) 0.76
Magnetic resonance in the detection of breast cancers of different histological types. Magn Reson Insights (2013) 0.76
Pleomorphic lobular carcinoma in situ: Current evidence and a systemic review. Oncol Lett (2016) 0.75
Lobular carcinoma in situ of the breast - correlation between minimally invasive biopsy and final pathology. Arch Med Sci (2016) 0.75
Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report. Int J Clin Exp Pathol (2011) 0.75
Carcinoma en cuirasse caused by pleomorphic lobular carcinoma of the breast in a man. JAAD Case Rep (2016) 0.75
Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat (2017) 0.75
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer (1978) 2.23
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res (2000) 1.82
Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr (1997) 1.68
Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol (1991) 1.65
Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol (2005) 1.40
Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer (2004) 1.40
Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res (1998) 1.33
Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol (2002) 1.24
Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol (2000) 1.21
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer (1996) 1.17
Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol (2001) 1.14
Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol (2008) 1.13
Overview of cancer epigenetics. Semin Hematol (2005) 1.12
The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer (2006) 1.10
Lobular carcinoma in situ: current concepts and controversies. Semin Diagn Pathol (1999) 1.05
Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases. Am J Surg Pathol (2006) 1.03
Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology (1993) 1.00
Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol (2008) 0.98
Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat (2005) 0.90
Comparative genomic hybridization. Curr Protoc Hum Genet (2001) 0.82
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell (2007) 3.97
Magnetic resonance imaging of the breast prior to biopsy. JAMA (2004) 3.97
Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology (2006) 3.42
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33
A non-genetic route to aneuploidy in human cancers. Nat Cell Biol (2011) 3.25
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med (2009) 2.97
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res (2008) 2.69
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol (2005) 2.36
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer (2005) 2.25
Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. Arch Pathol Lab Med (2008) 2.18
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res (2011) 2.11
Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin (2002) 2.07
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. Arch Pathol Lab Med (2014) 2.02
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Should intraoperative frozen section evaluation of breast lumpectomy margins become routine practice? Am J Clin Pathol (2012) 1.99
Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol (2007) 1.97
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94
Columnar cell lesions of the breast. Adv Anat Pathol (2003) 1.92
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
Surgical margins in lumpectomy for breast cancer--bigger is not better. N Engl J Med (2012) 1.91
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res (2005) 1.85
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol (2002) 1.82
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res (2012) 1.78
Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst (2011) 1.75
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res (2003) 1.71
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res (2004) 1.68
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med (2009) 1.67
Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol (2009) 1.67
Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol (2010) 1.65
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat (2011) 1.58
Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors. Arch Pathol Lab Med (2005) 1.57
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat (2010) 1.56
Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol (2004) 1.56
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res (2009) 1.56
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer (2004) 1.56
A call to standardize preanalytic data elements for biospecimens. Arch Pathol Lab Med (2013) 1.55
Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med (2010) 1.55
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol (2009) 1.54
Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going? Am J Clin Pathol (2003) 1.53
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. Histopathology (2014) 1.52
Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol (2002) 1.47
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Breast Cancer Res Treat (2012) 1.46
MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol (2005) 1.46
Ocular adnexal lymphoma and Helicobacter pylori gastric infection. Am J Hematol (2010) 1.45
The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer (2006) 1.44
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43
Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst (2012) 1.42